Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
Lopid 600 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Description Lopid 600 mg: white, biconvex, oval, film-coated tablets |
Each film-coated tablet contains 600 mg of gemfibrozil.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Gemfibrozil |
Gemfibrozil is a lipid regulating agent which regulates lipid fractions. Gemfibrozil stimulates the peripheral lipolysis of triglyceride rich lipoproteins such as VLDL and cholymicrons by stimulation of LPL. Gemfibrozil also inhibits synthesis of VLDL in the liver. |
| List of Excipients |
|---|
|
Core tablet: Microcrystalline cellulose Tablet coating: Hydroxypropylmethylcellulose (E464) |
Film-coated tablets: PVC/Aluminium blisters with 14, 20, 28, 30, 50, 56, 60, 98, 100, 196, 500 and 600 tablets.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
PL 00057/0535
Renewal of authorization: 04 April 2010
| Drug | Countries | |
|---|---|---|
| LOPID | Ecuador, Spain, Finland, Hong Kong, Ireland, Italy, Mexico, Netherlands, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
